This book embraces a comprehensive range of research across several disciplines, providing insights and fresh perspectives on clinical topics, emphasizing the integrative medical approach. The book also addresses an increasing role of artificial intelligence in the development of clinical methodologies, research, and patient-oriented care. The authors share expertise and experience in rehabilitation medicine whose healing-effects particularly depend on the interaction between the therapist and patient. Chapters present novel approaches in manual rehabilitative therapy of common painful and disabling neuromuscular ailments, exemplified but not limited to low back pain and migraine. The myofascial trigger point release therapy includes specific manipulations to muscles and connective tissue which reduce pain. Other chapters address the issues of providing long-range medical care to older adults burdened with chronic diseases, notably hypoxia-related pathologies and their sequalae, pointing to the advantages of care provided by a single primary care physician. Changing paradigm of care is essential in chronic atherosclerosis-based diseases like cardiovascular disorders or diabetes. Chapters provide results of international cohort studies on predictive factors for the long-range progress of such ailments based on anthropometric and lifestyle indicators. The book aims to meet the increasing interest and importance to patients of integrative health therapies. Medical rehabilitation and lifestyle changes increasingly gain scientific support in difficult-to-treat chronic conditions and should be integrated in a controlled manner into conventional medicine. The book is addressed to physiotherapists, medical scientists and clinicians, and allied healthcare professionals.

Over the past decade, significant efforts have been made to develop stem cell-based therapies for difficult to treat diseases. Multipotent mesenchymal stromal cells, also referred to as mesenchymal stem cells (MSCs), appear to hold great promise in regards to a regenerative cell-based therapy for the treatment of these diseases. Currently, more than 200 clinical trials are underway worldwide exploring the use of MSCs for the treatment of a wide range of disorders including bone, cartilage and tendon damage, myocardial infarction, graft-versus-host disease, Crohn s disease, diabetes, multiple sclerosis, critical limb ischemia and many others.

MSCs were first identified by Friendenstein and colleagues as an adherent stromal cell population within the bone marrow with the ability to form clonogenic colonies "in vitro. "In regards to the basic biology associated with MSCs, there has been tremendous progress towards understanding this cell population s phenotype and function from a range of tissue sources. Despite enormous progress and an overall increased understanding of MSCs at the molecular and cellular level, several critical questions remain to be answered in regards to the use of these cells in therapeutic applications. Clinically, both autologous and allogenic approaches for the transplantation of MSCs are being explored. Several of the processing steps needed for the clinical application of MSCs, including isolation from various tissues, scalable "in vitro "expansion, cell banking, dose preparation, quality control parameters, delivery methods and numerous others are being extensively studied. Despite a significant number of ongoing clinical trials, none of the current therapeutic approaches have, at this point, become a standard of care treatment. Although exceptionally promising, the clinical translation of MSC-based therapies is still a work in progress.

The extensive number of ongoing clinical trials is expected to provide a clearer path forward for the realization and implementation of MSCs in regenerative medicine. Towards this end, reviews of current clinical trial results and discussions of relevant topics association with the clinical application of MSCs are compiled in this book from some of the leading researchers in this exciting and rapidly advancing field. Although not absolutely all-inclusive, we hope the chapters within this book can promote and enable a better understanding of the translation of MSCs from bench-to-bedside and inspire researchers to further explore this promising and quickly evolving field.

The World Health Organization supports tools and initiatives in Health Impact Assessment to dynamically improve health and well-being across different sectors. Human Impact Assessment (HuIA) is a relatively new concept. It describes an integrated process that encompasses both Health Impact Assessment and Social Impact Assessment and is used to anticipate the effects of programs, projects and decisions on human health and welfare. Sleep occupies approximately one-third of our lives, but its human impact remains largely unrecognized. The prevalence of excessive sleepiness is recognized to be increasing in industrialized societies. Without doubt, sleepiness and fatigue have high costs in terms of both lives lost and socioeconomic impact. For example, the National Highway Traffic Safety Administration estimates that up to 4% of all fatal crashes are caused by drowsy drivers and that as many as 100,000 deaths per year in the United States may be due to fatigue-related medical errors. Sleepiness and Human Impact Assessment provides a uniquely comprehensive exploration of many different facets of sleepiness in our 24-hour society from the new HuIA point of view. Among the covered issues are the physiology and pathophysiology of sleep, its relationship to daytime alertness, fatigue and drugs, the relevance of sleep-related fatigue in various occupational settings and public safety. This book will be of assistance to physicians, occupational health professionals, ergonomists, researchers and decision-makers as they strive to understand the full significance of sleepiness and to create a culture of accountability in everyday life without sleep-related risks.

This book is a treatise on cardiomyocytes, the most important cell for the contractile function of the heart. There has been significant progress in our understanding of the function-related structure, developmental processes and their determinants, mechanisms of cell cycle regulation, post-natal growth, energy metabolism, and reversible and irreversible response of cardiomyocytes to diverse forms of physiological stress and injury. There is also more clarity on the alterations in the biological mechanisms in cardiomyocytes that lead to pathological states and the changes in the cells that occur secondary to disease conditions. Thanks to these advances in knowledge, there have been great gains in attempts to identify disease biomarkers and therapeutic targets for better management of patients with heart diseases. Possibilities to induce regeneration or proliferation of cardiomyocytes and thus repair and or regenerate the damaged heart are also on the horizon.

Medical Biosensors for Point of Care (POC) Applications discusses advances in this important and emerging field which has the potential to transform patient diagnosis and care. Part 1 covers the fundamentals of medical biosensors for point-of-care applications. Chapters in part 2 go on to look at materials and fabrication of medical biosensors while the next part looks at different technologies and operational techniques. The final set of chapters provide an overview of the current applications of this technology. Traditionally medical diagnostics have been dependent on sophisticated technologies which only trained professionals were able to operate. Recent research has focused on creating point-of-care diagnostic tools. These biosensors are miniaturised, portable, and are designed to be used at the point-of-care by untrained individuals, providing real-time and remote health monitoring.

Biomedical devices that contact with blood or tissue represent a wide range of products. Depending on their potential harm to a body, medical devices are categorized according to the degree, so their safety can be assured. All biomaterials are by definition designed to contact with a body for a certain period of time. The nature of the body contact, as well as the duration a material contacts with the body may initiate unwanted biological In comparison with invasive devices Oike catheters and medical responses. implants contact directly with tissue or with the circulating blood) non invasive devices (like wound-dressings and contact lenses contact with the skin, the sclera, and the mucosa or with open wounds) have a lesser risk of hurting a patient. When blood contacts with a foreign material, plasma proteins become absorpted to the surface within a few seconds. The reactions that follow, the so-called intrinsic pathway lead to the formation of fibrin and activation of platelets and white blood cells, result in blood clot formation."

Medicinal chemistry is both science and art. The science of medicinal chemistry offers mankind one of its best hopes for improving the quality of life. The art of medicinal chemistry continues to challenge its practitioners with the need for both intuition and experience to discover new drugs. Hence sharing the experience of drug research is uniquely beneficial to the field of medicinal chemistry. Drug research requires interdisciplinary team-work at the interface between chemistry, biology and medicine. Therefore, the topic-related series Topics in Medicinal Chemistry covers all relevant aspects of drug research, e.g. pathobiochemistry of diseases, identification and validation of (emerging) drug targets, structural biology, drugability of targets, drug design approaches, chemogenomics, synthetic chemistry including combinatorial methods, bioorganic chemistry, natural compounds, high-throughput screening, pharmacological in vitro and in vivo investigations, drug-receptor interactions on the molecular level, structure-activity relationships, drug absorption, distribution, metabolism, elimination, toxicology and pharmacogenomics. In general, special volumes are edited by well known guest editors.

As an addition to the European postgraduate training system for young neurosurgeons, we began to publish in 1974 this series of Advances and Technical Standards in Neurosurgery which was later sponsored by the European Association of Neurosurgical Societies. This series was first discussed in 1972 at a combined meeting of the Italian and German Neurosurgical Societies in Taormina, the founding fathers of the series being Jean Brihaye, Bernard Pertuiset, Fritz Loew and Hugo Krayenbuhl. Thus were established the principles of European co operation which have been born from the European spirit, flourished in the European Association, and have been associated throughout with this senes. The fact that the English language is now the international medium for communication at European scientific conferences is a great asset in terms of mutual understanding. Therefore we have decided to publish all contri butions in English, regardless of the native language of the authors. All contributions are submitted to the entire editorial board before publication of any volume for scrutiny and suggestions for revision. Our series is not intended to compete with the publications of original scientific papers in other neurosurgical journals. Our intention is, rather, to present fields of neurosurgery and related areas in which important recent advances have been made. The contributions are written by specialists in the given fields and constitute the first part of each volume.

* Innovative clinical trial design * Regulatory approval * Real world evidence

With new statistical and scientific issues arising in adaptive clinical trial design, including the U.S. FDA's recent draft guidance, a new edition of one of the first books on the topic is needed. Adaptive Design Methods in Clinical Trials, Second Edition reflects recent developments and regulatory positions on the use of adaptive designs in clinical trials. It unifies the vast and continuously growing literature and research activities on regulatory requirements, scientific and practical issues, and statistical methodology. New to the Second EditionAlong with revisions throughout the text, this edition significantly updates the chapters on protocol amendment and clinical trial simulation to incorporate the latest changes. It also includes five entirely new chapters on two-stage adaptive design, biomarker adaptive trials, target clinical trials, sample size and power estimation, and regulatory perspectives. Following in the tradition of its acclaimed predecessor, this second edition continues to offer an up-to-date resource for clinical scientists and researchers in academia, regulatory agencies, and the pharmaceutical industry. Written in an intuitive style at a basic mathematical and statistical level, the book maintains its practical approach with an emphasis on concepts via numerous examples and illustrations.

The development of more effective treatments for neuropsychiatric disorders requires scientific progress on a broad front. Animal models have a vital role to play in advancing the field. When deployed in conjunction with detailed study of these diseases in man they bring the power to make controlled experimental interventions which allow the functional consequences of genetic variations and polymorphisms to be understood in terms of their cellular, systems and behavioural effects. Further, they provide a means by which complex cognitive and behavioural phenomena may be dissected and understood. Finally, they provide a bridge to understanding the effects of drugs on the functioning of the central nervous system, thereby improving our understanding of the actions of those drugs in man.

Agile Implementation describes the underlying theories and frameworks that explain health delivery systems and lays out the 8 steps of the Agile Implementation Model founded by Malaz Boustani, MD, MPH and Jose Azar, MD. In today's complex healthcare environment, implementing evidence-based care into real-world practices is difficult and time consuming. Even methods that are known to be effective allow for limited flexibility and therefore fail as often as they succeed. Through much study and experimentation, Malaz Boustani, MD, MPH, Jose Azar, MD, and Craig A. Solid, PhD have come to understand how individuals' interactions within the complex social systems of hospitals, clinics, and other care delivery organizations shape the decisions and behaviors of those involved. Upon this foundation and through leveraging theories of behavioral economics, we have developed the Agile Implementation Model, a process for selecting, adapting, implementing, evaluating, sustaining, and scaling evidence-based healthcare interventions. This model acknowledges the uniqueness of each individual facility and considers individuals within the system to be semiautonomous but interconnected. In tandem with illustrative examples, Agile Implementation describes the underlying theories and frameworks that explain health delivery systems and lays out the 8 steps of the Agile Implementation Model. Upon completing Agile Implementation, readers have a better understanding of why certain quality initiatives succeed while others fail and have tangible, actionable tools for implementing effective and sustainable change in the healthcare setting.

Biopharmaceuticals (i.e., biological medicines sourced from genetically-engineered living systems) for treatment of human diseases have become a significant percentage of the pharmaceutical industry. And not just the recombinant DNA-derived proteins and monoclonal antibodies (both from the innovators and biosimilars); but now, an increasing awareness of the importance of gene therapy and genetically engineered cellular medicinal products. These biopharmaceuticals are being developed by many companies whose Chemistry, Manufacturing & Control (CMC) teams have varying degrees of familiarity or experience with the CMC strategy and regulatory compliance requirements for these challenging products. Companies clearly plan out the strategy for their clinical study plans, but frequently, the development of a strategy for CMC is an afterthought. Coupled with the complexity of the biopharmaceutical manufacturing processes and products, and this can be a recipe for disaster. The third edition of this book provides insights and practical guidance for the CMC teams to develop an acceptable cost-effective, risk-based CMC regulatory compliance strategy for all biopharmaceuticals (recombinant proteins, monoclonal antibodies, genetically engineered viruses and genetically engineered human cells) from early clinical stage development through market approval. The third edition of this book provides added coverage for the biosimilars, antibody drug conjugates (ADCs), bispecific antibodies, genetically engineered viruses, and genetically engineered cells. This third edition of the book also addresses the heightened pressure on CMC regulatory compliance timelines due to the introduction of expedited clinical pathways moving the clinical development closer to a seamless phase process (e.g., FDA Breakthrough Therapy designation, CBER Regenerative Medicine Advanced Therapy (RMAT) designation, EMA Priority Medicines (PRIME) designation). The Challenge of CMC Regulatory Compliance for Biopharmaceuticals is essential, practical information for all pharmaceutical development scientists, Manufacturing and Quality Unit staff, Regulatory Affairs personnel, and senior management involved in the manufacture of biopharmaceuticals.

The Pacific Symposium on Biocomputing (PSB) 2023 is an international, multidisciplinary conference for the presentation and discussion of current research in the theory and application of computational methods in problems of biological significance. Presentations are rigorously peer reviewed and are published in an archival proceedings volume. PSB 2023 will be held on January 3-7, 2023 in Kohala Coast, Hawaii. Tutorials and workshops will be offered prior to the start of the conference.PSB 2023 will bring together top researchers from the US, the Asian Pacific nations, and around the world to exchange research results and address open issues in all aspects of computational biology. It is a forum for the presentation of work in databases, algorithms, interfaces, visualization, modeling, and other computational methods, as applied to biological problems, with emphasis on applications in data-rich areas of molecular biology.The PSB has been designed to be responsive to the need for critical mass in sub-disciplines within biocomputing. For that reason, it is the only meeting whose sessions are defined dynamically each year in response to specific proposals. PSB sessions are organized by leaders of research in biocomputing's 'hot topics.' In this way, the meeting provides an early forum for serious examination of emerging methods and approaches in this rapidly changing field.

This book focus on genetic diagnostics for Uniparental Disomy (UPD), a chromosomal disorder defined by the exceptional presence of a chromosome pair derived from only one parent, which leads to a group of rare diseases in humans. First the molecular and cytogenetic background of UPD is described in detail; subsequently, all available information of the various chromosomal origins and the latest findings on genotype-phenotype correlations and clinical consequences are discussed. Numerous personal reports from families with a child suffering from a UPD-induced syndrome serve to complement the scientific and clinical aspects. Their experiences with genetic counseling and living with a family member affected by this chromosomal aberration present a vivid picture of what UPD means for its victims.

In recent years, many animal-derived polymers have emerged as an attractive category of naturally derived polymers because of their advantageous physicochemical, chemical, and biological properties. The important biological properties of these natural polymers derived from animals are biocompatibility and biodegradation. These polymers are generally composed of repeated units of amino acids. Moreover, these polymers can be modified physically and/or chemically to improve their biomaterial properties. Natural Polymers for Pharmaceutical Applications, Volume 3: Animal-Derived Polymers looks at how these polymers can be exploited as pharmaceutical excipients in various pharmaceutical dosage forms, like microparticles, nanoparticles, ophthalmic preparations, gels, implants, etc. The commonly used animal-derived polymers used as pharmaceutical excipients are hyaluronic acid (hyaluronan), albumin, collagen, gelatin, chondroitin, etc.

Project managers in drug development are the driving force behind the coordination of efforts. This book provides a practical reference for project managers in the pharmaceutical and biotech drug development industry, with the goal of assisting in creating an efficient and effective team structure and environment. The text details the role of project managers at each stage of drug development, the key interfaces that the PM will need to work closely with, and essential tools of the trade including frequently used techniques and methodologies. This book is useful for both entry-level and advanced-level PMs, as well as non-project managers from other functions. Features Includes authors' recent experience with improved tactics and technologies/software at various stages of drug development. Provides the most up-to-date and best practices, techniques, and methodologies in project management. Details the role of the PM at each stage of drug development, including working with the key interfaces throughout the process. Diverse audience including nonproject managers in clinical development, clinical operations, regulatory affairs, medical affairs, clinical pharmacology, and biostatistics. Provides templates and timelines for critical paths from development to commercialization and has potential as a textbook on relevant courses.

This volume provides systematic reviews of the state of clinical and health services research, in particular patient-care problem areas pertinent to nursing homes. Each chapter defines progress on a specific nursing home clinical problem and provides a critical synthesis and review of research information. Topics covered include: medication use; infection control; pressure ulcers; falls; urinary incontinence; and behavioural problems.

E-health two-side Markets: Implementation and Business Models presents empirical models and suggestions that focus on how to remove barriers to deliver online services across borders and how actual barriers affect business models in a two-sided market with regard to eHealth. Technological innovation and business developments in online trade result in fast-evolving markets with the continuous emergence of new products and services, thus requiring a specific approach. This book discusses how to develop innovative and cost-effective implementation strategies for complex organizations, the importance of barriers and facilitators for two-sided markets when implementing e-health services and/or IT based innovations, which pre-requisites have to be achieved in complex organizations that act in two-sided markets when implementing e-services, the ecosystem for implementation of services and innovations in complex organizations, and its effects for business models. This book is a valuable source for researchers in medical informatics, and is also ideal for stakeholders, consultants, advisors, and product designers involved in eHealth services.

It is my hope that subsequent volumes of the series will join this volume in assisting in the more complete understanding of the causes, diagnosis, and cell-based treatment of major human diseases and debilitating tissue/organ injuries. There exists a tremendous, urgent demand by the public and the scientific community to address to cancer diagnosis, treatment, cure, and hopefully prevention. Stem Cells are nature's indispensable gift to multicellular organisms, including humans. The contents of the volume are divided into six subheadings: Stem Cell Culture, Bone Marrow Stem Cells, Mesenchymal Stem Cells, Reprogramming and Differentiation of Stem Cells, Treatment, and Transplantation for the convenience of the readers.

This volume consists of four chapters that cover a structurally diverse range of naturally occurring compounds. Chapter 1 delves into the chemistry of pyrogallols and their oxidized products, the hydroxy-o-quinones, including their role in cycloaddition reactions in the chemical synthesis of several fungal metabolites. Chapter 2 provides an in-depth description of the constituents of agarwood essential oil and smoke samples that are used in the perfumery industry, with an emphasis on the sesquiterpenoid and chromones constituents so far known. Chapter 3 discusses the defensive chemical ecology of two North American newt species that both produce tetrodotoxin, a well-known neurotoxin that causes paralysis and death in metazoans by disrupting electrical signals in the nerves and muscles. Chapter 4 discusses the limonoids and triterpenoids from the genus Walsura of the plant family Meliaceae, of which a number of species are utilized in several southeastern Asian countries in systems of folk medicine.

This third edition volume expands on the previous editions with updated chapters on longitudinal studies, randomized trials, evidence-based decisions making, and a new section on changing health-related behaviors. The chapters in this book are organized into six parts: Part One focuses on framing clinical research questions and choosing a suitable design; biases that may occur in clinical research; and the ethics associated with doing conducting research on humans. Parts Two through Four discuss designs, measurements, and analysis that pertain to evaluation of risk in longitudinal studies; assessment of therapy in controlled trials; and evaluation of diagnostic tests. Part Five presents methods used in various components of evidence-based decision-making; and Part Six highlights interventions focused on changing health-related behaviors. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of various types of bias, step-by-step, readily reproducible protocols for different research designs, and tips on troubleshooting and avoiding known pitfalls. Cutting-edge and thorough, Clinical Epidemiology: Methods and Protocols, Third Edition is a valuable resource for clinicians and researchers who want to expand their works to humans and use their findings in the health system.

Patient-focused healthcare, driven by COVID-19 experiences, has become a hallmark for providing healthcare services to patients across all modalities of care and in the home. The ability to capture real-time patient data, no matter the location, via remote patient monitoring, and to transmit that data to providers and organizations approved by the consumer/patient, will become a critical capability for all healthcare providers. Of all the remote patient monitoring product designs, wearable medical devices are emerging as the best positioned to support the evolving patient-focused healthcare environment. This book is for those who are evaluating, selecting, implementing, managing, or designing wearable devices to monitor the health of patients and consumers. This book will provide the knowledge to understand the issues that mitigate the risk of wearable technologies so people can deliver successful projects using these technologies. It will discuss their use in remote patient monitoring, the advantages and disadvantages of different types of physiological sensors, different wireless communication protocols, and different power sources. It will describe issues and solutions in cybersecurity and HIPAA compliance, as well as setting them up to be used in healthcare systems and by patients.

Advances in Clinical Chemistry, Volume 77, the latest installment in this internationally acclaimed series, contains chapters authored by world-renowned clinical laboratory scientists, physicians, and research scientists. The serial discusses the latest and most up-to-date technologies related to the field of clinical chemistry and is the benchmark for novel analytical approaches in the clinical laboratory.

The growing knowledge on tumor-immune response interactions and on the tumor microenvironment did not translate so far into better control of cancer by anti-tumor vaccination. The percentage of patients who benefited from vaccination strategies is still too small to justify their general use. It is the aim of this book to present an alternative to the conventional approach of developing injected tumor vaccines to activate anti-tumor immunity, which will fight cancer. It is argued that in situ tumor ablation (destruction) that involves tumor antigen release; cross presentation and the release of danger associated molecular patterns (DAMPs) can make the tumor its own cellular vaccine. Tumor ablation methods using chemicals, radiation, photodynamic therapy, cryoablation, high-temperature, radiofrequency, high intensity focused ultrasound, and electric-based ablation have been developed for focal tumors. In this book experts will deal with two main topics: I. What are the principles of the various ablation modalities, and II. How each method affects the tumor cells and their microenvironment, and how these effects are responsible for the induction of specific anti-tumor immunity. The aims of this book are thus: 1. Familiarize the readers with various methods of in situ tumor ablation. 2. Review the literature and stimulate comparisons on the efficacy of different ablation methods for the treatment of tumors of different histotypes. 3. Review the literature on the effects of various ablation methods on systemic and local anti tumor immunity and on other manifestations of the interactions of tumors with their microenvironment. 4. Stimulate comparative studies on the immunostimulatory effects of different ablation modalities.